HirshJTherapyDrug. Heparin. N Engl J Med1991; 324:1565–1574.
2.
HyersTIVIHullRDWegJG. Antithrombotic therapy for venous thromboembolic disease. Chest1995; 108 (4):335S–351S.
3.
BrandjesDPMHeijboerHBullerHRde RijkMJagtHten CateM.Acenocoumarof and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med1992; 327:1485–1489.
4.
DurouxPNinetJBachetPA randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb & Haemost1991; 65:251–256.
5.
BraftGTornebohnEGranqvistSAbergWLocknerD. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb & Haemost1985; 54 (4):813–817.
6.
HolmHALyBHandelandGFSubcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemost1986; 16:30–37.
7.
PrandoniPLensingAWABullerHRComparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet1992; 339:441–445.
8.
HullRDRaskobGEPineoGFSubcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med1992; 326:975–982.
9.
GouldMKDembitzerADDoyleRLHastieTJGarberAM. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med1999; 130:800–809.
10.
LevineMGentMHirshJLeclercJAndersonDWeitzJGinsbergJTurpieAGG. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med1996; 334 (11):677–681.
11.
KoopmanMMWPrandoniPPiovellaF (for the TASMAN Study Group). Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med1996; 334 (11):682–687.
12.
HyersTIVIAgnellilGHullRDWegJGAntithrombotic therapy for venous thromboembolic disease. Chest1998; 114 (5):561S–578S.
13.
HirshJ. Oral Anticoagulant Drugs. N Engl J Med1991; 324:18651875.
14.
GallusAJackamanJTilletJEfficacyWWycherleyA. Safety and of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet1986; 11:1293–196.
15.
HullRDRaskobGERosenbloomDPanjuAABrill-EdwardsPGinsbergJSHirshJMartinGJGreenD. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med1990; 322:1260–126.
16.
CoonWWWillisPW. Recurrence of venous thromboembolism. Surgery1973; 73:823–827.
17.
HullRDDelmoreTGentonEWarfarin sodium versus lowdose heparin in the long-term treatment of venous thrombosis. N Engl J Med1979; 301:855–859.
18.
HullRDDelmoreTCarterCAdjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med1982; 306:189–194.
19.
HullRDHirshJJayRDifferent intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med1982; 307:1676–1681.
20.
Research Committee of the British Thoracic Society. Optimal duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet1992; 340:873–876.
21.
PrandoniPLensingAWABullerHRDeep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med1993; 327:1128–1133.
22.
SchulmanSRhedinASLindmarkerPCarissonAA comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med1995; 332 (25):1661–1665.
23.
SchulmanSGranqvistSHolmstromMCarissonAThe duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med1997; 336:393–398.
24.
KearonCGentMHirshJWeitzJKovacsMJAndersonDRTurpieAGGTGreenDGinsbergJSWellsPMacKinnonBJulianJA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med1999; 340:901–907.
